Last updated: September 4, 2026
AG-881, now called vorasidenib and marketed in the United States as Voranigo, is an oral dual inhibitor of mutant IDH1 and IDH2 developed by Agios Pharmaceuticals and acquired by Servier. The drug received FDA approval on Aug. 6, 2024, for adults and adolescents aged 12 years and older with grade 2 astrocytoma or oligodendroglioma carrying susceptible IDH1 or IDH2 mutations after surgery, including biopsy, subtotal resection, or gross total resection.[1]
Vorasidenib is the first FDA-approved therapy specifically directed at IDH-mutant diffuse glioma. Its commercial opportunity is concentrated in a molecularly defined, relatively small brain-tumor population. A base-case U.S. peak-sales estimate of approximately $500 million to $800 million is reasonable, with upside toward $1 billion if treatment duration is long, international approvals expand, and use moves into earlier-line or combination settings.
What is the current development status of AG-881?
Vorasidenib has completed development in the initial target population and is commercially available in the United States.
FDA regulatory milestones
| Milestone |
Date |
Status |
| AG-881 entered clinical development |
2010s |
Completed |
| Phase 1 dose-escalation and expansion studies |
2010s |
Completed |
| Phase 3 INDIGO study initiated |
2020 |
Completed |
| FDA Breakthrough Therapy designation |
2023 |
Granted |
| NDA accepted for priority review |
2024 |
Completed |
| FDA approval as Voranigo |
Aug. 6, 2024 |
Approved |
| Initial indication |
2024 |
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery |
| Dosage form |
2024 |
Oral tablets, 10 mg and 40 mg |
| Recommended adult and adolescent dose |
2024 |
40 mg once daily |
The approved indication is narrower than the entire IDH-mutant glioma market. Vorasidenib is indicated after surgery when immediate radiation and chemotherapy are not required. The FDA label specifies that treatment should continue until disease progression or unacceptable toxicity.[1]
What did the INDIGO trial show?
The pivotal INDIGO trial was a randomized, double-blind, placebo-controlled Phase 3 study involving 331 patients with residual or recurrent grade 2 IDH-mutant glioma. Patients had undergone surgery but had not yet received radiation or chemotherapy.
The primary endpoint was progression-free survival. Vorasidenib produced a median progression-free survival of 27.7 months compared with 11.1 months for placebo. The hazard ratio for disease progression or death was 0.39.[2]
The study also showed a delay in the time to the next intervention:
| Endpoint |
Vorasidenib |
Placebo |
| Median progression-free survival |
27.7 months |
11.1 months |
| Hazard ratio |
0.39 |
Reference |
| Median time to next intervention |
17.8 months at interim analysis |
11.4 months |
| IDH mutation target |
IDH1 or IDH2 |
N/A |
The clinical value is tied to delaying radiation and cytotoxic chemotherapy. That positioning may improve adoption among patients and physicians seeking to preserve neurocognitive function and defer treatment-related toxicity.
What is the FDA status and Orange Book position for Voranigo?
Voranigo is FDA-approved and subject to the standard U.S. prescription-drug regulatory framework. The FDA granted regular approval based on the INDIGO results rather than accelerated approval.[1]
What is the approved use?
The approved population consists of patients with:
- Grade 2 astrocytoma or oligodendroglioma
- A susceptible IDH1 or IDH2 mutation
- Age 12 years or older
- Prior surgery, biopsy, subtotal resection, or gross total resection
- No prior radiation or systemic chemotherapy for the current disease setting
The drug requires molecular confirmation of IDH status. This makes diagnostic testing a commercial prerequisite. The relevant testing market includes next-generation sequencing panels and immunohistochemistry for common IDH1 mutations.
Orange Book and patent information
FDA approval does not by itself establish a single, permanent generic-entry date. The commercial exclusivity analysis depends on listed patents, pediatric exclusivity, regulatory exclusivity, patent-term adjustment, and any Paragraph IV litigation.
Voranigo received seven years of orphan-drug exclusivity in the United States, which generally protects the approved orphan indication through August 2031, subject to statutory exceptions.[1] The approval also carries five years of new chemical entity exclusivity unless the product qualifies for other applicable extensions.
The core patent estate is expected to include composition-of-matter, therapeutic-use, and pharmaceutical-composition claims. Publicly available patent records should be reviewed against the FDA Orange Book for current patent numbers, expiration dates, and any pediatric patent-term extension before making a launch decision. The principal commercial protection is likely to extend beyond the five-year NCE period through issued patent claims, but the exact generic-entry date depends on the patents listed for Voranigo and the outcome of any Paragraph IV challenge.
When does vorasidenib lose exclusivity?
The earliest practical U.S. generic-entry window is unlikely to be before the early 2030s for the approved orphan indication.
| Protection |
Approximate end point |
Commercial effect |
| New chemical entity exclusivity |
2029 |
Blocks ANDA approval based on NCE protection |
| Orphan-drug exclusivity |
2031 |
Protects the approved orphan indication |
| Composition and use patents |
Potentially early-to-late 2030s |
May delay or complicate generic launch |
| Pediatric exclusivity |
Possible six-month extension |
Depends on FDA-requested pediatric studies |
| Formulation or method patents |
Potentially later than core protection |
May support narrower litigation positions |
A generic could seek approval through a Paragraph IV certification before patent expiration. That would create potential litigation and a 30-month stay if the NDA holder filed suit within the statutory period. A generic launch before final patent expiry would carry litigation and damages risk.
Which companies are challenging vorasidenib?
No major public Paragraph IV challenge should be treated as established without a current FDA Orange Book review and litigation-docket check. The likely future challengers are large generic manufacturers with oncology capabilities, including Teva, Sandoz, Viatris, Sun Pharma, Dr. Reddy's, and Hikma. Their commercial interest will depend on the size of the treated population, remaining patent life, product complexity, and whether the market supports more than one generic entrant.
Vorasidenib is a small-molecule tablet rather than a biologic, so biosimilar competition is not relevant. Competition will come through abbreviated new drug applications, off-label use of alternative IDH inhibitors, and future branded therapies.
What formulations and methods of use protect AG-881?
Vorasidenib is supplied as oral tablets in 10 mg and 40 mg strengths. The principal formulation value is operational rather than technological: once-daily oral dosing supports chronic outpatient treatment and avoids infusion infrastructure.
Potentially relevant patent categories include:
- The vorasidenib chemical entity and stereochemical forms.
- Pharmaceutical compositions containing vorasidenib.
- Methods of treating IDH1- or IDH2-mutant glioma.
- Methods of delaying radiation or chemotherapy.
- Dosing regimens for chronic administration.
- Use in defined molecular subgroups.
- Combination treatment with radiotherapy, temozolomide, or other targeted agents.
Method-of-use patents may remain commercially useful after composition patents expire, but their ability to prevent generic substitution depends on claim scope, labeling, physician behavior, and the generic's proposed label. Formulation claims may have weaker practical value if a generic can design around them while producing a therapeutically equivalent tablet.
What development programs remain for vorasidenib?
Vorasidenib's largest development opportunity is expansion beyond the initial post-surgical grade 2 setting.
Key development directions
| Development direction |
Commercial rationale |
Risk |
| Pediatric diffuse glioma |
Supports label expansion and pediatric exclusivity |
Small patient population |
| Grade 3 IDH-mutant glioma |
Enlarges the addressable market |
Standard-of-care therapy is more intensive |
| Newly diagnosed disease |
Moves treatment earlier in the disease course |
Requires stronger overall-survival and safety evidence |
| Combination with radiation |
Could improve disease control |
May increase neurotoxicity and logistical complexity |
| Combination with temozolomide |
Addresses higher-risk disease |
Competitive with established generic chemotherapy |
| Recurrent IDH-mutant glioma |
Expands use after progression |
More difficult treatment population |
| Other IDH-mutant solid tumors |
Broadens the platform |
Limited clinical validation outside glioma |
Agios previously evaluated vorasidenib in multiple IDH-mutant cancers, while Servier controls current global development and commercialization. The clearest near-term opportunity is label expansion within diffuse glioma, not a broad solid-tumor franchise.
How strong is the patent estate for vorasidenib?
The estate is commercially meaningful but not immune to challenge.
Strengths
- FDA approval in a genetically defined disease creates a clear use case.
- Orphan-drug exclusivity protects the approved indication through approximately 2031.
- The drug has composition and method-of-use patent opportunities.
- Chronic oral treatment can produce recurring revenue before generic entry.
- Generic development may be less attractive than in large primary-care markets because the patient population is small and molecularly selected.
Weaknesses
- The treated population is limited.
- Generic tablets are generally easier to develop than complex biologics.
- Use patents can be vulnerable to label carve-outs and non-infringing prescribing.
- The approval is concentrated in grade 2 disease, limiting immediate revenue.
- Physician adoption depends on long-term data, treatment sequencing, and neurocognitive outcomes.
The overall estate should be viewed as moderate to strong for the initial commercial period, with the most defensible value coming from the approved product, orphan exclusivity, and clinical differentiation rather than from formulation complexity.
How does vorasidenib compare with competing IDH inhibitors?
Vorasidenib has a distinct position because it was designed for central nervous system penetration and demonstrated benefit in nonenhancing IDH-mutant glioma.
| Product |
Company |
Target |
Primary position |
Competitive status |
| Voranigo |
Servier |
IDH1/IDH2 |
Grade 2 IDH-mutant glioma after surgery |
FDA-approved |
| Tibsovo |
Servier |
IDH1 |
AML and cholangiocarcinoma |
Approved in other diseases |
| Tazverik |
Ipsen |
EZH2 |
Select hematologic and solid tumors |
Not a direct IDH competitor |
| Ivosidenib |
Servier |
IDH1 |
AML, cholangiocarcinoma, other IDH1 settings |
Potential mechanistic alternative |
| Enasidenib |
Bristol Myers Squibb |
IDH2 |
Relapsed or refractory AML |
Not approved for glioma |
Ivosidenib and enasidenib are not interchangeable with vorasidenib. Their regulatory indications and central nervous system profiles differ. Off-label use may occur, but vorasidenib has the strongest evidence and regulatory positioning for IDH-mutant diffuse glioma.
What generic entry risks exist for Voranigo?
The most likely launch scenarios are:
Scenario 1: Delayed generic entry
A generic company waits until core patents and orphan exclusivity approach expiry, then launches after a non-infringing label or patent settlement. This scenario preserves branded revenue through approximately 2031 or later.
Scenario 2: Paragraph IV litigation
A generic files an ANDA with a Paragraph IV certification. Servier sues, producing a potential 30-month stay. A settlement could authorize entry before patent expiration while preserving some branded revenue.
Scenario 3: Early launch after patent invalidation
A court invalidates or narrows key patents, allowing launch before the expected expiration date. This is the highest downside scenario for Servier but requires a successful validity or non-infringement challenge.
Scenario 4: Limited substitution
A generic enters but achieves modest share because prescribing remains concentrated among neuro-oncology centers and treatment is linked to molecular testing. This would slow price erosion relative to high-volume chronic medicines.
What is the market projection for vorasidenib?
The addressable U.S. population is likely in the low thousands of treated patients annually, not the tens of thousands typical of large oncology markets. The opportunity depends on incidence, IDH mutation prevalence, eligibility after surgery, diagnosis rates, treatment duration, and access.
Base-case commercial model
| Metric |
Base-case assumption |
| U.S. eligible patients treated annually at maturity |
2,000-3,500 |
| Annual net price assumption |
$130,000-$170,000 |
| Average treatment duration |
18-30 months |
| Mature U.S. revenue |
$300 million-$600 million |
| Global revenue at maturity |
$500 million-$800 million |
| Peak sales timing |
2029-2033 |
| Generic erosion |
Begins around early 2030s, subject to patents |
The published U.S. list price was reported at approximately $15,500 per 28-day cycle, equivalent to about $201,500 before discounts on a 13-cycle basis. Net revenue will be lower because of commercial rebates, government discounts, patient assistance, and payer negotiations.[3]
Upside case
Peak global sales could exceed $1 billion if:
- Vorasidenib gains approval in grade 3 disease.
- Treatment is used earlier and for longer periods.
- Pediatric adoption expands.
- European and other international markets reimburse broadly.
- The company demonstrates a meaningful overall-survival or neurocognitive benefit.
- Combination studies support use across multiple treatment sequences.
Downside case
Sales could remain below $400 million globally if:
- The grade 2 market is smaller than expected.
- Treatment duration is short.
- Payers impose molecular-testing or step-therapy restrictions.
- Radiation and chemotherapy remain preferred for higher-risk disease.
- Safety concerns limit chronic use.
- Patent challenges accelerate generic entry.
What revenue exposure does Voranigo create for Servier?
Voranigo is strategically important because Servier acquired Agios' oncology portfolio and obtained rights to vorasidenib in the transaction structure. The drug gives Servier a differentiated U.S. oncology asset with recurring oral revenue and limited direct competition.
The commercial concentration creates risk. A meaningful proportion of the product's value is tied to one molecular subgroup and one tumor family. Servier's return will depend on launch execution, diagnostic penetration, international pricing, and successful label expansion.
What litigation and settlement issues should investors monitor?
Key monitoring points include:
- FDA Orange Book patent listings for Voranigo.
- ANDA filings with Paragraph IV certifications.
- District-court complaints filed by Servier.
- Inter partes review petitions at the Patent Trial and Appeal Board.
- Settlement agreements that establish an authorized-generic date.
- Patent-term adjustment and pediatric-study extensions.
- Label changes affecting grade 3, pediatric, or combination use.
- Reimbursement decisions by major U.S. payers.
- Competitor data involving other brain-penetrant IDH inhibitors.
No biosimilar litigation is expected because Voranigo is a small molecule. The relevant legal pathway is ANDA litigation, not the Biologics Price Competition and Innovation Act pathway.
Key Takeaways
- AG-881 is vorasidenib, marketed as Voranigo by Servier.
- The FDA approved it on Aug. 6, 2024, for patients aged 12 years and older with grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery.
- INDIGO showed median progression-free survival of 27.7 months versus 11.1 months with placebo.
- U.S. orphan exclusivity should protect the approved indication through approximately August 2031.
- The product has no biosimilar risk; future challenges will come from generic manufacturers.
- The core commercial market is small but high value, with a base-case global peak-sales range of $500 million to $800 million.
- Grade 3, pediatric, recurrent-disease, and combination indications are the main upside opportunities.
- Patent and Paragraph IV developments will determine whether generic entry begins in the early 2030s or earlier.
- The patent estate is commercially useful but should be analyzed together with Orange Book listings, litigation, and claim scope.
FAQs
Is AG-881 the same drug as vorasidenib?
Yes. AG-881 was the development code for vorasidenib, which is marketed in the United States as Voranigo.
What mutation is required for Voranigo treatment?
Treatment requires a susceptible mutation in IDH1 or IDH2, confirmed through an FDA-authorized diagnostic approach.
Can Voranigo replace radiation and temozolomide?
The approved use is intended for patients after surgery who do not require immediate radiation or chemotherapy. It does not establish that vorasidenib replaces those treatments in higher-risk or grade 3 disease.
Is vorasidenib approved for recurrent glioblastoma?
No. The FDA approval is for grade 2 astrocytoma or oligodendroglioma with susceptible IDH1 or IDH2 mutations after surgery. Glioblastoma is not the approved indication.
What is the main investment risk for Voranigo?
The main risks are the limited molecularly defined market, uncertain treatment duration, dependence on label expansion, reimbursement pressure, and generic or patent challenges beginning around the early 2030s.
References
- U.S. Food and Drug Administration. (2024). FDA approves vorasidenib for certain gliomas. https://www.fda.gov
- Mellinghoff, I. K., et al. (2023). Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. New England Journal of Medicine, 389(7), 589-601.
- Servier. (2024). Servier announces U.S. FDA approval of Voranigo (vorasidenib) tablets for patients with grade 2 astrocytoma or oligodendroglioma. https://www.servier.com
- National Cancer Institute. (2024). Vorasidenib and IDH-mutant glioma clinical development information. https://clinicaltrials.gov
- U.S. Food and Drug Administration. (2024). Voranigo prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/